23:09 , May 8, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
19:54 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

FDA wants more info on Sunovion Parkinson’s therapy

Sunovion Pharmaceuticals Inc. said late Jan. 30 that FDA issued a complete response letter for its NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson’s disease patients. The subsidiary of Sumitomo Dainippon...
20:36 , Jan 31, 2019 |  BC Extra  |  Company News

FDA wants more info on Sunovion Parkinson’s therapy

Sunovion Pharmaceuticals Inc. said late Wednesday that FDA issued a complete response letter for its NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson’s disease patients. The subsidiary of Sumitomo Dainippon Pharma...
19:52 , Jan 17, 2019 |  BioCentury  |  Regulation

Products on shutdown standby

Products on shutdown standby On Jan. 14, FDA said it has reserves to continue drug reviews for five more weeks if the government shutdown continues. There are at least six PDUFA dates for new products...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
18:12 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Neurology company Aquestive raises $67.5M IPO

Aquestive Therapeutics Inc. (NASDAQ:AQST) added $1.05 to $16.05 on July 25 after raising $67.5 million through the sale of 4.5 million shares at $15 in an upsized IPO. Underwriters were BMO Capital Markets, RBC Capital...